$2.91
0.34% today
Nasdaq, Feb 28, 05:15 pm CET
ISIN
IL0011326795
Symbol
PYPD
Sector
Industry

Polypid Ltd Stock price

$2.92
-0.23 7.30% 1M
-0.59 16.81% 6M
-0.12 3.95% YTD
-2.56 46.67% 1Y
-118.28 97.59% 3Y
-567.08 99.49% 5Y
-567.08 99.49% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.18 5.81%
ISIN
IL0011326795
Symbol
PYPD
Sector
Industry

Key metrics

Market capitalization $29.76m
Enterprise Value $23.57m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 3.87
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-28.03m
Cash position $15.81m
EPS (TTM) EPS $-4.93
P/E forward negative
Short interest 0.08%
Show more

Is Polypid Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Polypid Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Polypid Ltd forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Polypid Ltd forecast:

Buy
80%
Hold
20%

Financial data from Polypid Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.22 5.22
22% 22%
-
- Research and Development Expense 23 23
41% 41%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -28 -28
23% 23%
-
Net Profit -29 -29
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polypid Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polypid Ltd Stock News

Neutral
Seeking Alpha
16 days ago
PolyPid Ltd. (NASDAQ:PYPD ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Chase Knickerbocker - Craig-Hallum Ram Selvar...
Neutral
GlobeNewsWire
16 days ago
Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in March 202 5 , with T op- L ine Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrant s Expected to ...
Neutral
GlobeNewsWire
29 days ago
PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025.
More Polypid Ltd News

Company Profile

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID–500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

Head office Israel
CEO Dikla Akselbrad
Employees 61
Founded 2008
Website www.polypid.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today